This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label
by Zacks Equity Research
United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.
UTHRNegative Net Change RGENPositive Net Change ACIUPositive Net Change AMRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
by Zacks Equity Research
EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.
EYPTNegative Net Change REGNNegative Net Change BAYRYNegative Net Change AMRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?
by Ekta Bagri
Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.
LQDANegative Net Change JNJNegative Net Change UTHRNegative Net Change
biotechnology biotechs medical pharmaceuticals
NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?
by Sundeep Ganoria
Neurocrine's shares fell 12% in a month as Vykat XR safety concerns mount, but Ingrezza and Crenessity support growth.
NBIXNegative Net Change BMYNegative Net Change TEVANegative Net Change
biotechs medical pharmaceuticals
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
by Ahan Chakraborty
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
SDGRNegative Net Change RLAYNegative Net Change RXRXNegative Net Change ABSINegative Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
by Zacks Equity Research
Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
OTLKNegative Net Change
biotechnology biotechs earnings
Can BMY's First CELMoD Approval Support Its Growth Strategy?
by Zacks Equity Research
Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?
by Sundeep Ganoria
AbbVie's neuroscience franchise posts strong first-half growth, with Vyalev accelerating and tavapadon poised to add another potential growth driver.
ABBVNegative Net Change BIIBNegative Net Change JNJNegative Net Change
biotechs earnings marijuana pharmaceuticals
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
by Sundeep Ganoria
ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.
ANIPNegative Net Change REGNNegative Net Change ABBVNegative Net Change
biotechs medical
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
by Sundeep Ganoria
Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.
ANIPNegative Net Change REGNNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals